| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Bode John B is a Director at ZVRA. Recent filings cover 10 purchases and 0 sales. Those positions are worth an estimated $955K at current prices.
Our model assigns Bode John B a middling insider score of 66/100, based on 5 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +38.7%.
Bode John B's largest disclosed position is in ZVRA as Director, worth about $955K. Net of sales, the recent Form 4 record there shows accumulation of 45,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2025 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 5,000 | $9.17 | $45,825.00 | +12.5% | +1.9% | - | |
| Mar 19, 2025 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $7.96 | $79,624.00 | +33.3% | +10.8% | +18.2% | |
| Jul 12, 2024 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $5.87 | $58,661.00 | +50.0% | +35.4% | +114.2% | |
| Sep 5, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $5.13 | $51,333.00 | +100.0% | +0.8% | +42.9% | |
| May 18, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 10,000 | $5.04 | $50,417.69 | +48.2% | +2.8% | -6.3% |